ABIVAX Société Anonyme (NASDAQ:ABVX) Stock Price Up 4.6% – What’s Next?

ABIVAX Société Anonyme (NASDAQ:ABVX) was up 4.6% on Thursday . The stock traded as high as $8.27 and last traded at $8.21. Approximately 60,369 shares were traded during trading, a decline of 41% from the average daily volume of 103,118 shares. The stock had previously closed at $7.85.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Citizens Jmp raised shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. JMP Securities restated a “market outperform” rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $38.67.

ABIVAX Société Anonyme Stock Performance

The firm has a 50 day moving average price of $6.81 and a 200-day moving average price of $8.96.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Large investors have recently bought and sold shares of the stock. abrdn plc boosted its stake in shares of ABIVAX Société Anonyme by 34.1% during the fourth quarter. abrdn plc now owns 424,181 shares of the company’s stock valued at $3,105,000 after acquiring an additional 107,750 shares during the last quarter. GAMMA Investing LLC purchased a new position in ABIVAX Société Anonyme in the 4th quarter valued at about $29,000. Point72 Asset Management L.P. boosted its stake in shares of ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after purchasing an additional 119,300 shares during the last quarter. Walleye Capital LLC grew its holdings in shares of ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after buying an additional 80,807 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after acquiring an additional 5,900 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.